Smiles: CC(C)=CCC1=C2OC(=C(O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O[C@@H]3OC[C@@H](O)[C@H](O)[C@H]3O)C(=O)C2=C(O)C=C1O)C1C=CC(O)=CC=1
Small Molecule Inhibition of the Autophagy Kinase ULK1 and Identification of ULK1 Substrates
Smiles: CC(C)N(C1=CC=C(F)C=C1F)C(=O)N1C=NN(C2=CC=C(Cl)C=C2Cl)C1=O
) significantly increases the ambulation of mice at 0
5)32(38)39
Dinaciclib - CAS# 779353-01-4 Catalog No.:M10712-10 Smiles: CC(C)=CCC1=C2OC(=C(O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O[C@@H]3OC[C@@H](O)[C@H](O)[C@H]3O)C(=O)C2=C(O)C=C1O)C1C=CC(O)=CC=1Dinaciclib, also known as SCH727965, is a potent CDK inhibitor with potential antineoplastic activity. Dinaciclib selectively inhibits cyclin dependent kinases CDK1, CDK2, CDK5, and CDK9 activity in vitro with IC(50) values of 1, 1, 3, and 4 nmol L, respectively. Compared with flavopiridol, Dinaciclib exhibits superior activity with an improved therapeutic index. Dinaciclib induced regression of established solid tumors in a range of mouse models